LODOCO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lodoco, and what generic alternatives are available?
Lodoco is a drug marketed by Agepha Pharma Fz and is included in one NDA. There are thirteen patents protecting this drug.
This drug has eighty-eight patent family members in twenty-five countries.
The generic ingredient in LODOCO is colchicine. There are sixteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the colchicine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lodoco
A generic version of LODOCO was approved as colchicine by AMNEAL PHARMS on September 28th, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LODOCO?
- What are the global sales for LODOCO?
- What is Average Wholesale Price for LODOCO?
Summary for LODOCO
| International Patents: | 88 |
| US Patents: | 13 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 4 |
| Drug Prices: | Drug price information for LODOCO |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LODOCO |
| What excipients (inactive ingredients) are in LODOCO? | LODOCO excipients list |
| DailyMed Link: | LODOCO at DailyMed |
Recent Clinical Trials for LODOCO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Virginia Commonwealth University | PHASE1 |
| University of Texas Southwestern Medical Center | Phase 2 |
| University of Sao Paulo | NA |
Pharmacology for LODOCO
| Drug Class | Alkaloid |
US Patents and Regulatory Information for LODOCO
LODOCO is protected by fourteen US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agepha Pharma Fz | LODOCO | colchicine | TABLET;ORAL | 215727-001 | Jun 16, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Agepha Pharma Fz | LODOCO | colchicine | TABLET;ORAL | 215727-001 | Jun 16, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Agepha Pharma Fz | LODOCO | colchicine | TABLET;ORAL | 215727-001 | Jun 16, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Agepha Pharma Fz | LODOCO | colchicine | TABLET;ORAL | 215727-001 | Jun 16, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Agepha Pharma Fz | LODOCO | colchicine | TABLET;ORAL | 215727-001 | Jun 16, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Agepha Pharma Fz | LODOCO | colchicine | TABLET;ORAL | 215727-001 | Jun 16, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LODOCO
See the table below for patents covering LODOCO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2014255434 | ⤷ Start Trial | |
| Australia | 2019201048 | ⤷ Start Trial | |
| Australia | 2020294268 | ⤷ Start Trial | |
| Australia | 2024205185 | ⤷ Start Trial | |
| Brazil | 112015026418 | ⤷ Start Trial | |
| Canada | 2909370 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch